In Reply.

mRNA tests for screening or surveillance. Given the strength of the initial validation data, we caution the readers of Obstetrics & Gynecology that the authors’ conclusions are not adequately supported by their data and that both FDA-approved mRNA and DNA HPV tests should continue to be used as outlined in screening and surveillance guidelines from the ASCCP, the U.S. Preventive Services Task Force, the American Cancer Society, and the American College of Obstetricians and Gynecologists.